Electronic Supplementary Information

Impacts of Coordination Modes on Red-Emitting Cyclometalated Iridium Complexes

Chenggang Jiang and Thomas S. Teets*

University of Houston, Department of Chemistry 3585 Cullen Blvd., Room 112, Houston, TX USA 77204-5003.

*Corresponding author: tteets@uh.edu

Index	Page
Experimental section	S2–S7
Summary of X-ray crystallographic data	S8–S10
NMR spectra of all new compounds	S11–S20
IR-spectra	S21–S25
Molecular structure of Ir-piq-L ₃ H-B	S26
NMR spectra showing thermal conversion of 2-picolinamide isomers	S27
Cyclic voltammograms of complexes with an extended scan window	S28
Excitation spectra	S29–S33
Time-resolved photoluminescence decay traces	S34–S43
ESI References	S44

Experimental section

Materials

Solvents for photophysical and electrochemical measurements were obtained from a Grubbs Solvent Purification System and degassed with argon. Commercially available starting materials and reagents were used without further purification. Tetrabutylammonium hexafluorophosphate, used as a supporting electrolyte for cyclic voltammetry experiments, was recrystallized from hot ethanol, and ferrocene, used as an internal standard for cyclic voltammetry experiments, was purified by sublimation. The iridium dimers of the general formula $[Ir(C^N)_2(\mu-Cl)]_2 (C^N = cyclometalating ligand)$ were prepared by following literature procedures,¹ refluxing $IrCl_3 \cdot xH_2O$ with 2.1 equivalents of the C^N ligand in a 3:1 2-methoxyethanol/water mixture. All the ancillary ligands used in this study were prepared following literature procedures.^{2–5}

Physical Methods

¹H, and ¹³C 1 H} NMR spectra were recorded at room temperature using a JEOL ECA-400, ECA-500, or ECA-600 NMR spectrometer. The ESI-MS experiments were conducted at The University of Texas at Austin's Mass Spectrometry Facility or Texas A&M University Chemistry Department Mass Spectrometry Facility. UV-vis absorption spectra were measured in toluene solutions in 1 cm quartz cuvettes sealed with a screw cap and septum, using an Agilent Cary 8454 UV-vis spectrophotometer. Steady-state emission spectra were measured using a Horiba FluoroMax-4 spectrofluorometer with appropriate long-pass filters to exclude stray excitation light from detection. To exclude air, samples for emission spectra were prepared in a nitrogen-filled glovebox using dry, deoxygenated solvents, and thin-film PMMA samples were kept under nitrogen until immediately before measurement. Emission quantum yields were determined relative to a standard of tetraphenylporphyrin (TPP) in toluene, which has a reported fluorescence quantum yield (Φ_F) of 0.11.⁶ The absolute quantum yields of complexes doped into poly(methyl methacrylate) (PMMA) thin films were recorded using a Spectralon-coated integrating sphere integrated with a Horiba FluoroMax-4 spectrofluorometer. Cyclic voltammetry (CV) measurements were performed with a CH Instruments 602E potentiostat using a three-electrode system in a nitrogen-filled glovebox. A 3 mm diameter glassy-carbon electrode, Pt wire, and silver wire were used as the working electrode, counter electrode, and pseudoreference electrode, respectively. Measurements were performed in acetonitrile solution with 0.1 M TBAPF₆ as a supporting electrolyte at a scan rate of 0.1 V/s. Ferrocene was used as an internal standard, and potentials were referenced to the ferrocene/ferrocenium couple.

PMMA Film Fabrication

A solution of PMMA (98 mg, 35 kDa) in dichloromethane (1.0 mL) was prepared at room temperature in a nitrogen-filled glovebox. Then, the respective iridium complex (2 mg, 2 wt%) was added to the solution and stirred until a homogeneous solution was given. The resulting solution was then drop-coated on a quartz substrate and dried at room temperature overnight.

X-ray Crystallography Details

Single crystals of **Ir-btp-L¹**, **Ir-btp-L²**, **Ir-piq-L⁶**, **Ir-piq-L³H-B**, **Ir-pphen-L⁵-B**, and **Ir-piq-L⁸** were grown by vapor diffusion of pentane or diethyl ether vapor into concentrated THF or

CH₂Cl₂ solutions. Crystals were mounted on a Bruker Apex II three-circle diffractometer using MoK α radiation ($\lambda = 0.71073$ Å). The data were collected at 123(2) K and processed and refined within the APEXII software. Structures were solved by using intrinsic phasing in SHELXT and refined by standard difference Fourier techniques in the SHELXL program.⁷ All non-hydrogen atoms were refined with anisotropic displacement parameters. Hydrogen atoms bonded to carbon were fixed in calculated positions using the standard riding model and were refined isotropically. The structures of $Ir-btp-L^1$ and $Ir-pphen-L^5-B$ included heavily disordered solvent electron density that could not be modeled, necessitating the use of the SQUEEZE command in PLATON.⁸ In the structure of Ir-pphen-L⁵-B, disorder was observed in one of the cyclometalating ligands and in the solvent molecules. All disordered parts were restrained with distance restraints (SADI in SHELX) and rigid-bond restraints (SIMU and DELU in SHELX). The crystals of Ir-piq-L³H-B were extremely small and weakly diffracting. The crystal dimension was 0.07×0.05×0.01 mm, and the crystal diffracted poorly at high resolution, leading to some significant level A and level B checkCIF errors after refinement. As a result, the structural metrics (bond distances and bond lengths) in Ir-piq-L³H-C are not very reliable and the CIF file was not deposited in CCDC, but the final refined model conclusively confirms the proposed molecular structure.

Synthesis

General procedure for preparation of salicylaldimine complexes. The chloro-bridged cyclometalated iridium dimer was treated with 5 equivalents of Na₂CO₃ in 10 mL of ethanol and stirred for 1h, then 2.1 equivalents of the salicylaldimine ligand ($L^{N}H$) were added. The reaction mixture was refluxed overnight. After the solvent was removed under vacuum, the residue was re-dissolved in CH₂Cl₂ and then filtered through a thin neutral alumina oxide layer, using CH₂Cl₂ as the eluent to flush out the product.

Preparation of [Ir(btp)₂L¹] (Ir-btp-L¹). Prepared by the general procedure using [Ir(btp)₂(μ -Cl)]₂ (100 mg, 0.077 mmol) and L¹H (27 mg, 0.17 mmol). The resulting crude product was further purified by recrystallization from CH₂Cl₂/pentane to give a red solid. Yield: 67 mg, 56%. ¹H NMR (600 MHz, CD₂Cl₂) δ 8.76 (d, J = 5.8 Hz, 1H, btp Ar*H*), 8.43 (d, J = 7.2 Hz, 1H, Ar*H*), 8.02 (s, 1H, N=CHAr), 7.78 (t, J = 7.9 Hz, 1H, Ar*H*), 7.73 (t, J = 7.7 Hz, 1H, Ar*H*), 7.65 (d, J = 8.0 Hz, 2H, Ar*H*), 7.59 (d, J = 8.1 Hz, 1H, Ar*H*), 7.18 (t, J = 8.7 Hz, 1H, Ar*H*), 7.12 – 7.03 (m, 2H, Ar*H*), 7.01 (t, J = 6.6 Hz, 1H, Ar*H*), 6.92 (dd, J = 15.8, 7.3 Hz, 2H, Ar*H*), 6.83 (t, J = 7.6 Hz, 1H, Ar*H*), 6.78 (t, J = 7.7 Hz, 1H, Ar*H*), 6.60 (d, J = 8.6 Hz, 1H, Ar*H*), 6.54 (d, J = 8.1 Hz, 1H, Ar*H*), 6.39 (t, J = 7.7 Hz, 1H, Ar*H*), 6.29 (d, J = 8.1 Hz, 1H, Ar*H*), 6.01 (d, J = 8.2 Hz, 1H, Ar*H*), 3.13 – 3.02 (m, 2H, CH₂CH₂CH₃), 1.21 – 1.10 (m, 1H, CH₂CH₂CH₃), 1.07 – 0.95 (m, 1H, CH₂CH₂CH₃), 0.15 (t, J = 7.3 Hz, 3H, CH₂CH₂CH₃). ¹³C {¹H} NMR (151 MHz, CD₂Cl₂) δ 166.3, 166.1, 165.1, 161.8, 151.3, 150.3, 150.0, 148.9, 147.1, 146.7, 142.8, 142.6, 138.5, 138.4, 136.6, 135.4, 135.2, 134.2, 125.8, 125.5, 125.4, 125.1, 124.7, 124.1, 124.0, 123.6, 123.1, 123.0, 120.8, 119.7, 119.6, 119.2, 118.3, 113.7, 66.4, 24.6, 11.5. HRMS-ESI (*m*/z): [M+H]⁺ calcd for C₃₆H₂₈IrN₃OS₂, 776.1374; found, 776.1158.

Preparation of [Ir(btp)₂L²] (**Ir-btp-L**²). Prepared by the general procedure using [Ir(btp)₂(μ -Cl)]₂ (100 mg, 0.077 mmol) and L₂H (34 mg, 0.16 mmol). The resulting crude product was further purified by recrystallization from CH₂Cl₂/pentane to give a red solid. Yield: 83 mg, 65%. ¹H NMR (600 MHz, CDCl₃) δ 8.92 (d, J = 5.5 Hz, 1H, btp Ar*H*), 8.79 (d, J = 5.5 Hz, 1H, Ar*H*),

7.91 (s, 1H, N=CHAr), 7.43 – 7.37 (m, 1H, Ar*H*), 7.29 (d, J = 7.8 Hz, 1H, Ar*H*), 7.22 (s, 1H, Ar*H*), 7.12 – 7.11 (m, 1H, Ar*H*), 7.06 (ddd, J = 8.8, 6.8, 1.9 Hz, 1H, Ar*H*), 6.97 – 6.93 (m, 2H, Ar*H*), 6.83 – 6.71 (m, 7H, Ar*H*), 6.67 (d, J = 8.0 Hz, 1H, Ar*H*), 6.54 – 6.48 (m, 1H, Ar*H*), 6.34 (ddd, J = 7.9, 6.9, 1.1 Hz, 1H, Ar*H*), 6.28 (d, J = 8.1 Hz, 2H, Ar*H*), 6.06 (tdd, J = 7.3, 5.8, 1.5 Hz, 3H, Ar*H*), 1.83 (s, 3H, Ar*CH*₃). The poor solubility of this compound precluded ¹³C{¹H} NMR analysis. HRMS-ESI (m/z): [M+Na]⁺ calcd for C₄₀H₂₈IrN₃OS₂, 846.1194; found, 846.1172.

Preparation of [Ir(pphen)_2L^1] (Ir-pphen-L¹). Prepared by the general procedure using $[Ir(pphen)_2(\mu-Cl)]_2$ (30 mg, 0.020 mmol) and L₁H (7 mg, 0.043 mmol). The resulting crude product was further purified by recrystallization from CH₂Cl₂/pentane to give a red solid. Yield: 22 mg, 63%. ¹H NMR (600 MHz, CD₂Cl₂) δ 9.46 (d, J = 8.5 Hz, 1H, pphen ArH), 9.08 – 9.02 (m, 2H, ArH), 8.77 (d, J = 8.2 Hz, 1H, ArH), 8.54 (d, J = 8.0 Hz, 1H, ArH), 8.42 (d, J = 8.2 Hz, 1H, ArH), 8.32 (d, J = 8.1 Hz, 1H, ArH), 8.25 (d, J = 8.1 Hz, 1H, ArH), 8.13 (d, J = 7.9 Hz, 1H, ArH), 7.97 (d, J = 8.4 Hz, 1H, ArH), 7.94 (t, J = 7.8 Hz, 1H, ArH), 7.83 (dd, J = 14.5, 7.4 Hz, 2H, ArH), 7.75 (t, J = 7.5 Hz, 1H, ArH), 7.55 (t, J = 7.3 Hz, 1H, ArH), 7.47 (t, J = 7.6 Hz, 1H, ArH), 7.44 (t, J = 7.8 Hz, 1H, ArH), 7.38 (t, J = 7.8 Hz, 1H, ArH), 7.25 (s, 1H, N=CHAr), 7.06 (d, J = 7.7 Hz, 1H, ArH), 7.02 (t, J = 7.7 Hz, 1H, ArH), 6.98 (t, J = 7.3 Hz, 1H, ArH), 6.65 (t, J = 7.4 Hz, 1H, ArH), 6.59 (t, J = 7.3 Hz, 1H, ArH), 6.39 (d, J = 7.3 Hz, 1H, ArH), 6.33 (ddd, J = 8.2, 7.0, 1.5 Hz, 1H, ArH), 6.15 (dd, J = 7.4, 1.3 Hz, 1H, ArH), 5.80 (d, J = 8.4 Hz, 1H, ArH), 5.76 (t, J = 7.3 Hz, 1H, ArH), 3.38 - 3.28 (m, 1H, CH₂CH₂CH₃), 3.07 - 2.98 (m, 1H, $CH_2CH_2CH_3$, 0.81 – 0.72 (m, 1H, $CH_2CH_2CH_3$), 0.25 – 0.15 (m, 4H, $CH_2CH_2CH_3$). ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 174.8, 174.6, 168.0, 165.2, 154.3, 153.4, 149.3, 147.8, 146.1, 143.2, 138.1, 134.4, 134.0, 133.8, 132.7, 132.3, 132.2, 131.8, 131.2, 131.0, 130.5, 129.9, 129.5, 129.5, 128.9, 127.7, 127.3, 127.02, 127.00, 126.9, 126.7, 125.8, 125.6, 124.7, 123.5, 123.3, 122.5, 122.4, 122.3, 122.0, 121.4, 121.3, 119.5, 112.4, 61.7, 24.4, 11.4. HRMS-ESI (m/z): [M+Na]⁺ calcd for C48H36IrN3O, 886.2383; found, 886.2364.

Preparation of [Ir(piq)₂L⁶] (Ir-piq-L⁶). Prepared by the general procedure using [Ir(piq)₂(μ -Cl)]₂ (100 mg, 0.079 mmol) and L⁶H (50 mg, 0.19 mmol). The resulting crude product was further purified by recrystallization from CH₂Cl₂/pentane to give a red solid. Yield: 80 mg, 59%. ¹H NMR (500 MHz, CDCl₃) δ 9.00 – 8.95 (m, 1H, piq Ar*H*), 8.87 (d, J = 6.3 Hz, 1H, Ar*H*), 8.75 (d, J = 6.3 Hz, 1H, Ar*H*), 8.53 (d, J = 8.6 Hz, 1H, Ar*H*), 8.17 (d, J = 8.0 Hz, 1H, Ar*H*), 8.06 (s, 1H, Ar*H*), 7.91 (d, J = 8.1 Hz, 1H, Ar*H*), 7.88 – 7.83 (m, 1H, Ar*H*), 7.73 – 7.67 (m, 3H, Ar*H*), 7.66 – 7.59 (m, 2H, Ar*H*), 7.47 (d, J = 6.4 Hz, 1H, Ar*H*), 7.36 (d, J = 6.4 Hz, 1H, Ar*H*), 7.17 (t, J = 8.8 Hz, 1H, Ar*H*), 6.67 (t, J = 6.0 Hz, 1H, Ar*H*), 6.91 (t, J = 6.9 Hz, 1H, Ar*H*), 6.80 (d, J = 8.2 Hz, 2H, Ar*H*), 6.67 (t, J = 6.7 Hz, 1H, Ar*H*), 6.65 – 6.59 (m, 2H, Ar*H*), 6.46 (t, J = 6.8 Hz, 1H, Ar*H*), 6.38 – 6.32 (m, 2H, Ar*H*), 6.24 (d, J = 6.3 Hz, 1H, Ar*H*), 6.13 (d, J = 8.0 Hz, 2H, Ar*H*). ¹³C {¹H} NMR (126 MHz, CD₂Cl₂) δ 169.8, 169.1, 167.8, 161.5, 154.8, 154.5, 146.2, 145.8, 141.7, 140.7, 137.0, 136.9, 134.7, 133.2, 130.8, 129.94, 129.93, 129.4, 129.1, 127.8, 127.4, 127.3, 127.2, 126.6, 126.1, 125.3, 125.0, 124.6, 122.7, 121.5, 121.0, 119.8, 113.6. HRMS-ESI (*m*/z): [M+H]⁺ calcd for C44H₂₉F₃IrN₃O, 866.1965; found, 866.1945.

Preparation of [Ir(piq)₂L³H][Cl] (Ir-piq-L³H-B). 1 equivalent of $[Ir(piq)_2(\mu-Cl)]_2$ (100 mg, 0.079 mmol) was mixed with 2.2 equivalents of L³H (29 mg, 0.18 mmol) in 10 mL of anhydrous THF and then the reaction mixture was kept at room temperature for 48 h. After the solvent was removed under vacuum, the residue was re-dissolved in CH₂Cl₂ and filtered through Celite. After evaporating the solvent, the resulting crude product was further purified by recrystallization from

CH₂Cl₂/pentane to give a red solid. Yield: 92 mg, 73%. ¹H NMR (500 MHz, CDCl₃) δ 11.80 (s, 1H, CON*H*), 9.95 (d, J = 8.0 Hz, 1H, Ar*H*), 9.00 – 8.93 (m, 2H, Ar*H*), 8.28 (d, J = 8.0 Hz, 1H, Ar*H*), 8.23 (d, J = 6.6 Hz, 2H, Ar*H*), 8.08 (t, J = 7.8 Hz, 1H, Ar*H*), 7.98 – 7.87 (m, 2H, Ar*H*), 7.80 – 7.73 (m, 4H, Ar*H*), 7.63 (d, J = 5.1 Hz, 1H, Ar*H*), 7.49 (d, J = 6.4 Hz, 1H, Ar*H*), 7.39 (t, J = 7.6 Hz, 1H, Ar*H*), 7.34 (d, J = 6.4 Hz, 1H, Ar*H*), 7.29 (d, J = 6.4 Hz, 1H, Ar*H*), 7.06 (t, J = 7.6 Hz, 1H, Ar*H*), 7.02 (t, J = 7.6 Hz, 1H, Ar*H*), 6.81 (t, J = 7.4 Hz, 1H, Ar*H*), 6.77 (t, J = 7.4 Hz, 1H, Ar*H*), 6.53 (d, J = 7.7 Hz, 1H, Ar*H*), 6.16 (d, J = 7.6 Hz, 1H, Ar*H*), 3.57 – 3.39 (m, 2H, CH₂CH₂CH₃), 1.53 – 1.38 (m, 2H, CH₂CH₂CH₃), 0.49 (t, J = 7.4 Hz, 3H, CH₂CH₂CH₃). ¹³C{¹H}</sup> NMR (151 MHz, CDCl₃) δ 171.3, 170.0, 168.0, 150.3, 149.5, 149.4, 148.3, 146.7, 145.3, 140.1, 139.9, 139.3, 137.3, 137.2, 133.2, 133.1, 131.7, 131.6, 130.6, 130.5, 130.4, 129.9, 129.5, 128.9, 128.7, 128.6, 127.9, 127.5, 127.2, 126.5, 126.4, 126.3 122.8, 121.6, 121.4, 121.3, 42.9, 22.1, 11.0. HRMS-ESI (*m*/*z*): [M–Cl]⁺ calcd for C₃₉H₃₂ClIrN₄O, 765.2196; found, 765.2202.

Preparation of [Ir(piq)₂L⁴-B] (Ir-piq-L⁴-B). After 2.5 equivalents of the L⁴H (42 mg, 0.20 mmol) were treated with 3 equivalents of sodium methoxide (13 mg, 0.24 mmol) in 10 mL THF and stirred for 10 min, 1 equivalent of $[Ir(piq)_2(\mu-Cl)]_2$ (100 mg, 0.079 mmol) was added. The reaction mixture was kept at room temperature overnight. After the solvent was removed under vacuum, the residue was re-dissolved in CH₂Cl₂ and filtered through Celite. After evaporating the solvent, the crude product was purified by column chromatography (silica gel stationary phase and CH_2Cl_2 /ethyl acetate gradient eluent). Previously reported Ir-piq-L⁴ is the less polar product that elutes first as the major product, and Ir-pig-L⁴-B is the more polar product that elutes second from the column. The eluate of the second fraction was concentrated in vacuo to give an orange solid. Yield: 22 mg, 17%. ¹H NMR (500 MHz, CDCl₃) δ 8.97 (t, J = 8.3 Hz, 2H, ArH), 8.73 (d, J = 6.4 Hz, 1H, ArH), 8.55 (d, J = 7.7 Hz, 1H, ArH), 8.26 (d, J = 8.0 Hz, 1H, ArH), 8.20 (d, J = 8.3 Hz, 1H, ArH), 7.90 – 7.85 (m, 1H, ArH), 7.82 (d, J = 7.5 Hz, 1H, ArH), 7.76 – 7.66 (m, 5H, ArH), 7.53 (d, J = 6.4 Hz, 1H, ArH), 7.49 (d, J = 5.0 Hz, 1H, ArH), 7.38 (d, J = 6.4 Hz, 1H, ArH), 7.34 (d, J = 8.2 Hz, 2H, L⁴ ArH), 7.23 (d, J = 6.6 Hz, 1H, ArH), 7.13 (t, J = 6.4 Hz, 1H, ArH), 7.00 (t, J = 7.5 Hz, 1H, ArH), 6.94 (t, J = 7.8 Hz, 1H, ArH), 6.87 (d, J = 8.1 Hz, 2H, L^4 ArH), 6.78 (t, J = 7.5 Hz, 1H, ArH), 6.69 (t, J = 7.5 Hz, 1H, ArH), 6.58 (d, J = 7.6 Hz, 1H, ArH), 6.21 (d, J = 7.9 Hz, 1H, ArH), 2.19 (s, 3H, CH₃). ${}^{13}C{}^{1}H{}$ NMR (101 MHz, CDCl₃) § 170.1, 168.0, 150.1, 149.9, 149.3, 147.7, 146.1, 145.3, 140.2, 140.1, 139.4, 137.29, 137.26, 136.3, 134.0, 133.1, 132.9, 131.8, 131.6, 130.8, 130.6, 130.5, 130.4, 129.9, 129.8, 129.3, 128.8, 128.7, 127.9, 127.6, 127.2, 126.6, 126.4, 126.3, 123.0, 122.1, 121.7, 121.63, 121.57, 21.1. HRMS-ESI (m/z): $[M+H]^+$ calcd for C₄₃H₃₁IrN₄O, 813.2202; found, 813.2194.

Preparation of [Ir(pphen)₂**L**⁵] (**Ir-pphen-L**⁵) and [**Ir(pphen)**₂**L**⁵-**B**] (**Ir-pphen-L**⁵-**B**). After 2.5 equivalents of **L**⁵**H** (23 mg, 0.086 mmol) were treated with 3 equivalents of sodium methoxide (6 mg, 0.11 mmol) in 10 mL of anhydrous THF and stirred for 10 min, 1 equivalent of [Ir(pphen)₂(μ -Cl)]₂ (50 mg, 0.034 mmol) was added. The reaction mixture was kept at room temperature overnight. After the solvent was removed under vacuum, the residue was redissolved in CH₂Cl₂ and filtered through Celite. After evaporating the solvent, the crude product was purified by column chromatography (silica gel stationary phase and CH₂Cl₂/ethyl acetate gradient eluent). The eluate from each fraction was concentrated in vacuo to give a red solid. The compound **Ir-pphen-L**₅ is the less polar product that elutes as the first fraction and is the major product. Yield: 20 mg, 61%. ¹H NMR (400 MHz, CDCl₃) δ 9.48 (d, J = 9.4 Hz, 1H, pphen Ar*H*), 9.02 (d, J = 8.3 Hz, 1H, Ar*H*), 8.64 (d, J = 8.2 Hz, 1H, Ar*H*), 8.54 (d, J = 8.0 Hz, 1H, Ar*H*), 8.44 (t, J = 7.0 Hz, 2H, Ar*H*), 8.28 (d, J = 8.1 Hz, 1H, Ar*H*), 8.22 (d, J = 5.4 Hz, 1H, Ar*H*),

8.02 (d, J = 8.4 Hz, 1H, Ar*H*), 7.94 – 7.86 (m, 2H, Ar*H*), 7.83 – 7.77 (m, 3H, Ar*H*), 7.75 (d, J = 7.9 Hz, 1H, Ar*H*), 7.58 – 7.48 (m, 3H, Ar*H*), 7.43 (qd, J = 8.4, 1.2 Hz, 2H, Ar*H*), 7.15 – 7.05 (m, 2H, Ar*H*), 6.98 – 6.83 (m, 3H, Ar*H*), 6.74 (t, J = 6.8 Hz, 1H, Ar*H*), 6.68 – 6.54 (m, 5H, Ar*H*), 6.44 (d, J = 8.6 Hz, 1H, Ar*H*). $^{13}C{^{1}H}$ NMR (151 MHz, CDCl₃) δ 173.8, 173.7, 170.8, 157.1, 156.2, 153.3, 148.9, 147.9, 147.6, 145.9, 143.5, 143.1, 137.2, 136.3, 134.1, 133.8, 133.0, 132.6, 132.1, 131.9, 130.8, 129.8, 129.74, 129.70, 129.5, 129.3, 128.2, 127.4, 127.3, 127.2, 126.63, 126.55, 126.52, 126.4, 125.6, 124.9, 124.8, 124.1, 124.0, 123.9, 123.8, 123.6, 123.5, 122.6, 122.4, 122.0, 121.6, 121.1, 120.7. HRMS-ESI (*m*/*z*): [M+Na]⁺ calcd for C₅₁H₃₂IrN4O, 989.2050; found, 989.2035.

Ir-pphen-L⁵-B is the more polar product that elutes as the second fraction. Yield: 9 mg, 27%. ¹H NMR (600 MHz, CDCl₃) δ 9.10 (d, J = 8.2 Hz, 1H, Ar*H*), 9.05 (d, J = 8.3 Hz, 1H, Ar*H*), 8.66 – 8.58 (m, 3H, Ar*H*), 8.42 (d, J = 8.2 Hz, 1H, Ar*H*), 8.41 – 8.35 (m, 2H, Ar*H*), 8.26 (d, J = 5.6 Hz, 1H, Ar*H*), 8.17 (d, J = 8.0 Hz, 1H, Ar*H*), 7.96 (t, J = 7.6 Hz, 1H, Ar*H*), 7.87 (t, J = 7.7 Hz, 2H, Ar*H*), 7.80 (t, J = 9.1 Hz, 2H, Ar*H*), 7.67 (d, J = 8.6 Hz, 1H, Ar*H*), 7.48 (t, J = 7.5 Hz, 1H, Ar*H*), 7.42 – 7.34 (m, 2H, Ar*H*), 7.28 (t, J = 7.8 Hz, 1H, Ar*H*), 7.17 (t, J = 8.8 Hz, 2H, Ar*H*), 7.08 (t, J = 6.4 Hz, 1H, Ar*H*), 7.04 (t, J = 7.5 Hz, 1H, Ar*H*), 7.01 (d, J = 8.1 Hz, 2H, Ar*H*), 6.95 (t, J = 7.8 Hz, 1H, Ar*H*), 6.66 (t, J = 7.4 Hz, 1H, Ar*H*), 6.47 (d, J = 8.1 Hz, 2H, Ar*H*), 6.44 (d, J = 7.6 Hz, 1H, Ar*H*). ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 174.0, 171.8, 166.3, 157.6, 154.7, 153.4, 151.3, 148.3, 147.5, 146.0, 144.2, 143.2, 139.2, 137.1, 136.2, 133.9, 133.7, 132.04, 131.97, 131.7, 131.0, 130.1, 129.7, 129.5, 129.1, 128.9, 127.7, 127.3, 127.2, 126.5, 126.3, 126.0, 125.8, 125.3, 124.9, 124.8, 123.6, 123.2, 122.8, 122.7, 121.6, 121.4, 120.8. HRMS-ESI (*m*/z): [M+H]⁺ calcd for C₅₁H₃₂IrN₄O, 967.2230; found, 967.2241.

Preparation of $[Ir(piq)_2L^7][PF_6]$ (Ir-piq-L⁷). 1 equivalent of $[Ir(piq)_2(\mu-Cl)]_2$ (100 mg, 0.079 mmol) was dissolved in CH_2Cl_2 and combined with 2.1 equivalents of AgPF₆ (42 mg, 0.17) mmol). Then 2.5 equiv of L⁷ (29 mg, 0.20 mmol) was added to the reaction mixture which was stirred at room temperature overnight. The completed reaction mixture was filtered through Celite to remove AgCl. The filtrate volume was reduced, and diethyl ether was added to precipitate the crude product. The solid was dried under vacuum. The resulting crude product was purified by recrystallization from CH₂Cl₂/hexane to give a red solid. Yield: 89 mg, 63%. ¹H NMR (500 MHz, CD₂Cl₂) δ 9.27 (s, 1H, ArH), 8.95 (d, J = 7.7 Hz, 1H, ArH), 8.90 (d, J = 9.1 Hz, 1H, ArH), 8.25 (q, J = 7.6 Hz, 3H, ArH), 8.05 (td, J = 7.8, 1.6 Hz, 1H, ArH), 8.00 – 7.93 (m, 2H, ArH), 7.89 (d, J = 6.5 Hz, 1H, ArH), 7.85 – 7.74 (m, 4H, ArH), 7.71 (d, J = 3.9 Hz, 1H, ArH), 7.53 (d, J = 6.4 Hz, 1H, ArH), 7.42 (d, J = 6.4 Hz, 1H, ArH), 7.39 (ddd, J = 7.8, 5.4, 1.4 Hz, 1H, ArH), 7.26 (d, J = 6.4 Hz, 1H, ArH), 7.12 – 7.04 (m, 2H, ArH), 6.89 – 6.79 (m, 2H, ArH), 6.25 (dd, J = 7.7, 1.3 Hz, 1H, ArH), 6.11 (dd, J = 7.6, 1.3 Hz, 1H, ArH), 3.71 – 3.59 (m, 2H, CH₂CH₂CH₃), 1.19 – 1.06 (m, 2H, CH₂CH₂CH₃), 0.40 (t, J = 7.4 Hz, 3H, CH₂CH₂CH₃). ¹³C{¹H} NMR (126 MHz, CD₂Cl₂) δ 169.2, 169.0, 168.2, 155.5, 152.9, 152.3, 150.7, 145.57, 145.55, 141.1, 140.5, 139.5, 137.1, 132.3, 132.02, 131.95, 131.6, 130.80, 130.76, 130.6, 130.5, 129.6, 129.3, 128.9, 128.8, 127.6, 127.5, 127.00, 126.98, 126.38, 126.35, 122.6, 122.3, 122.1, 121.9, 63.2, 22.6, 10.7. HRMS-ESI (*m/z*): [M-PF₆]⁺ calcd for C₃₉H₃₂IrN₄PF₆, 749.2251; found, 749.2238.

Preparation of $[Ir(piq)_2L^8]$ (Ir-piq-L⁸). 2.5 equivalents of L⁸H (59 mg, 0.20 mmol) were dissolved in THF and treated with a cold solution of *n*-BuLi (0.10 mL, 2.5 M in *n*-hexane, 0.25 mmol, 3.2 equivalents) at -35 °C for 1h. Then 1 equivalent of $[Ir(piq)_2(\mu-Cl)]_2$ (100 mg, 0.079

mmol) was added to the reaction mixture and stirred at room temperature overnight. After removing the solvent under vacuum, the residue was extracted with toluene and filtered through Celite. The filtrate was concentrated to about 2 mL, and 2 mL of hexane was added. The mixture was cooled to -35 °C for 2 days to obtain dark red crystals. The cold mixture was filtered, and the product was washed with 4 mL of pentane and dried under vacuum. Yield: 64 mg, 45%. ¹H NMR (500 MHz, CD₂Cl₂) δ 9.21 (d, J = 6.3 Hz, 1H, piq ArH), 9.02 (d, J = 6.4 Hz, 1H, ArH), 8.70 (d, J = 8.4 Hz, 1H, ArH), 8.63 (d, J = 8.5 Hz, 1H, ArH), 8.08 (s, 1H, ArN=CHAr), 7.96 (t, J = 8.4 Hz, 2H, L⁸ ArH), 7.76 – 7.61 (m, 6H, ArH), 7.53 (d, J = 6.0 Hz, 2H, L⁸ ArH), 7.07 (dd, J = 8.1, 1.9 Hz, 1H, ArH), 6.87 (ddd, J = 9.1, 6.5, 1.9 Hz, 1H, ArH), 6.60 – 6.51 (m, 2H, ArH), 6.43 (dd, J = 8.0, 2.2 Hz, 1H, ArH), 6.39 (d, J = 7.4 Hz, 2H, ArH), 6.33 (dd, J = 8.0, 2.3 Hz, 1H, 1H)ArH), 6.30 – 6.21 (m, 2H, ArH), 6.07 (d, J = 9.2 Hz, 1H, ArH), 6.05 – 5.97 (m, 5H, ArH), 5.84 (dd, J = 7.7, 1.3 Hz, 1H, ArH), 5.08 (dd, J = 8.0, 2.2 Hz, 1H, ArH), 2.01 (s, 3H, CH₃), 1.96 (s, 3H, CH₃). ${}^{13}C{}^{1}H$ NMR (126 MHz, CD₂Cl₂) δ 169.82, 169.80, 160.5, 159.6, 159.5, 151.8, 151.5, 149.7, 145.9, 145.0, 142.7, 142.6, 137.1, 136.9, 136.8, 133.51, 133.47, 132.4, 131.9, 130.67, 130.65, 130.5, 129.6, 129.4, 129.0, 128.3, 128.2, 127.7, 127.51, 127.49, 127.2, 127.14, 127.05, 126.7, 126.5, 126.1, 125.4, 125.3, 123.1, 119.8, 119.6, 119.4, 119.3, 118.9, 117.5, 110.1, 20.31, 20.28. HRMS-ESI (*m/z*): [M+Na]⁺ calcd for C₅₁H₃₉IrN₄, 923.2700; found, 923.2691.

	Ir-btp-L ¹	Ir-btp-L ²	Ir-piq-L ⁶
CCDC	2300731	2300732	2300733
Chemical formula	C ₃₆ H ₂₈ IrN ₃ OS ₂	C40H28IrN3OS2	C44H29F3IrN3O
M _r	774.93	822.97	864.90
Crystal system, space group	Trigonal, <i>R</i> 3:H	Triclinic, <i>P</i> T	Monoclinic, $P2_1/c$
Temperature (K)	123(2)	123	123
<i>a</i> , <i>b</i> , <i>c</i> (Å)	36.2343 (15), 36.2343 (15), 15.9108 (7)	10.7907 (11), 11.0742 (11), 14.2844 (14)	18.3303 (17), 11.9159 (11), 15.9378 (15)
α, β, γ (°)	90, 90, 120	107.087 (1), 102.368 (1), 93 .397 (1)	90, 106.937 (1), 90
$V(Å^3)$	18091.0 (17)	1580.0 (3)	3330.2 (5)
Ζ	18	2	4
μ (mm ⁻¹)	3.45	4.40	4.07
Crystal size (mm)	0.44 imes 0.30 imes 0.19	0.17 imes 0.14 imes 0.09	0.28 imes 0.1 imes 0.06
T_{\min}, T_{\max}	0.508, 0.746	0.613, 0.746	0.601, 0.746
No. of measured, independent and	31337, 8981, 7614	28181, 7275, 6228	20714, 7708, 6321
observed $[I > 2\sigma(I)]$ reflections			
R _{int}	0.046	0.066	0.042
$(\sin \theta / \lambda)_{max} (\text{\AA}^{-1})$	0.649	0.651	0.651
$R[F^2 > 2\sigma(F^2)], wR(F^2), S$	0.023, 0.047, 0.95	0.036, 0.070, 1.02	0.031, 0.065, 0.97
No. of reflections	8981	7275	7708
No. of parameters	389	425	469
No. of restraints	0	0	0
	$w = 1/[\sigma^2(F_o^2) + (0.0103P)^2]$ where $P = (F_o^2 + 2F_c^2)/3$	$w = 1/[\sigma^2(F_o^2) + (0.0265P)^2]$ where $P = (F_o^2 + 2F_c^2)/3$	$w = 1/[\sigma^2(F_o^2) + (0.0276P)^2]$ where $P = (F_o^2 + 2F_c^2)/3$
$\Delta \rho_{max}, \Delta \rho_{min} (e \text{ Å}^{-3})$	1.01, -1.18	0.90, -0.93	0.80, -0.84

Table S1. Summary of X-ray crystallographic data for complexes Ir-btp-L¹, Ir-btp-L² and Irpiq-L⁶.

	Ir-pphen-L ⁵ -B·2C ₄ H ₈ O
CCDC	2300734
Chemical formula	$C_{51}H_{31}F_3IrN_4O\cdot 2(C_4H_8O)$
M _r	1109.20
Crystal system, space group	Triclinic, <i>P</i> T
Temperature (K)	123
<i>a</i> , <i>b</i> , <i>c</i> (Å)	10.916 (4), 13.168 (4), 18.015 (6)
α, β, γ (°)	82.060 (5), 78.545 (5), 78.258 (5)
$V(Å^3)$	2472.0 (14)
Ζ	2
μ (mm ⁻¹)	2.76
Crystal size (mm)	$0.15 \times 0.07 \times 0.03$
T_{\min}, T_{\max}	0.647, 0.745
No. of measured, independent and	32112, 10180, 7894
observed $[I > 2\sigma(I)]$ reflections	
R _{int}	0.079
$(\sin \theta / \lambda)_{max} (\text{\AA}^{-1})$	0.629
$R[F^2 > 2\sigma(F^2)], wR(F^2), S$	0.049, 0.113, 0.99
No. of reflections	10180
No. of parameters	631
No. of restraints	1291
	$w = 1/[\sigma^2(F_o^2) + (0.0532P)^2]$
	where $P = (F_o^2 + 2F_c^2)/3$
$\Delta \rho_{\text{max}}, \Delta \rho_{\text{min}} (e \text{ Å}^{-3})$	1.15, -1.48

 Table S2. Summary of X-ray crystallographic data for the complex Ir-pphen-L⁵-B.

	Ir-piq-L ⁸
CCDC	2300735
Chemical formula	C44H32IrN3O
M _r	810.92
Crystal system, space group	Triclinic, <i>P</i> T
Temperature (K)	123(2)
<i>a</i> , <i>b</i> , <i>c</i> (Å)	9.2199 (4), 13.999 (2), 14.701 (2)
α, β, γ (°)	70.672 (2), 84.198 (2), 74.663 (2)
$V(\text{\AA}^3)$	1726.6 (5)
Ζ	2
$\mu (mm^{-1})$	3.91
Crystal size (mm)	$0.30 \times 0.21 \times 0.14$
T _{min} , T _{max}	0.576, 0.746
No. of measured, independent and	43010, 7957, 7324
observed $[I > 2\sigma(I)]$ reflections	
R _{int}	0.044
$(\sin \theta / \lambda)_{max} (\text{\AA}^{-1})$	0.651
$R[F^2 > 2\sigma(F^2)], wR(F^2), S$	0.022, 0.054, 1.04
No. of reflections	7957
No. of parameters	443
No. of restraints	0
	$w = 1/[\sigma^2(F_o^2) + (0.0312P)^2]$ where $P = (F_o^2 + 2F_c^2)/3$
$\Delta \rho_{\text{max}}, \Delta \rho_{\text{min}} (e \text{ Å}^{-3})$	1.39, -0.41

 Table S3. Summary of X-ray crystallographic data for the complex Ir-piq-L⁸.




Fig. S2. ¹³C{¹H} NMR spectrum of Ir-btp-L¹, recorded in methylene chloride- d_2 at 151 MHz.




Fig. S4. ¹H NMR spectrum of Ir-pphen-L¹, recorded in methylene chloride- d_2 at 600 MHz.




Fig. S6. ¹H NMR spectrum of Ir-piq-L⁶, recorded in chloroform-*d* at 500 MHz.




Fig. S7. ¹³C{¹H} NMR spectrum of Ir-piq-L⁶, recorded in methylene chloride- d_2 at 151 MHz.





Fig. S8. ¹H NMR spectrum of Ir-piq-L³H-B, recorded in chloroform-*d* at 500 MHz.






Fig. S10. ¹H NMR spectrum of Ir-piq-L⁴-B, recorded in chloroform-*d* at 500 MHz.




Fig. S12. ¹H NMR spectrum of Ir-pphen-L⁵, recorded in chloroform-*d* at 400 MHz.




Fig. S14. ¹H NMR spectrum of Ir-pphen-L⁵-B, recorded in chloroform-*d* at 600 MHz.




Fig. S15. ¹³C {¹H} NMR spectrum of Ir-pphen-L⁵-B, recorded in chloroform-d at 151 MHz.




Fig. S16. ¹H NMR spectrum of Ir-piq-L⁷, recorded in methylene chloride- d_2 at 500 MHz.




Fig. S17. ¹³C {¹H} NMR spectrum of Ir-piq-L⁷, recorded in methylene chloride- d_2 at 126 MHz.




Fig. S18. ¹H NMR spectrum of Ir-piq-L⁸, recorded in methylene chloride- d_2 at 500 MHz.




Fig. S19. ¹³C{¹H} NMR spectrum of Ir-piq-L⁸, recorded in methylene chloride- d_2 at 126 MHz.




Fig. S20. FTIR spectrum of free ligand L³H.




Fig. S21. FTIR spectrum of free ligand L^4H .




Fig. S22. FTIR spectrum of free ligand L^5H .




Fig. S23. FTIR spectrum of complex Ir-piq-L³.




Fig. S24. FTIR spectrum of complex Ir-piq-L³H-B.




Fig. S25. FTIR spectrum of complex Ir-piq-L⁴.




Fig. S26. FTIR spectrum of complex Ir-piq-L⁴-B.




Fig. S27. FTIR spectrum of complex Ir-ppphen-L⁵.




Fig. S28. FTIR spectrum of complex Ir-pphen-L⁵-B.




Fig. S29. Molecular structure of **Ir-piq-L³H-B**, determined by single-crystal X-ray diffraction. Thermal ellipsoids are shown at the 50% probability level. Hydrogen atoms bonded to carbon were omitted for clarity.




Fig. S30. Evolution of the ¹H NMR spectra of **Ir-piq-L⁴-B** while heating in THF- d_8 at 65 °C for 7 days.




Fig. S31. Evolution of the ¹H NMR spectra of **Ir-pphen-L⁵-B** while heating in THF- d_8 at 65 °C for 7 days.




Fig. S32. Cyclic voltammogram of Ir-piq-L⁶ in THF with 0.1 M TBAPF₆ electrolyte. The arrow indicates the scan direction.




Fig. S33. Cyclic voltammogram of **Ir-piq-L³H-B** in THF with 0.1 M TBAPF₆ electrolyte. The arrow indicates the scan direction.




Fig. S34. Overlaid, normalized UV–vis absorption (black solid line) and excitation (red dashed line) spectra of **Ir-btp-L**¹, recorded in toluene at room temperature.




Fig. S35. Overlaid, normalized UV–vis absorption (black solid line) and excitation (red dashed line) spectra of **Ir-btp-L**², recorded in toluene at room temperature.




Fig. S36. Overlaid, normalized UV–vis absorption (black solid line) and excitation (red dashed line) spectra of **Ir-pphen-L**¹, recorded in toluene at room temperature.




Fig. S37. Overlaid, normalized UV–vis absorption (black solid line) and excitation (red dashed line) spectra of **Ir-piq-L**⁶, recorded in toluene at room temperature.




Fig. S38. Overlaid, normalized UV–vis absorption (black solid line) and excitation (red dashed line) spectra of **Ir-piq-L³H-B**, recorded in toluene at room temperature.




Fig. S39. Overlaid, normalized UV–vis absorption (black solid line) and excitation (red dashed line) spectra of **Ir-piq-L⁴-B**, recorded in toluene at room temperature.




Fig. S40. Overlaid, normalized UV–vis absorption (black solid line) and excitation (red dashed line) spectra of **Ir-pphen-L**⁵, recorded in toluene at room temperature.




Fig. S41. Overlaid, normalized UV–vis absorption (black solid line) and excitation (red dashed line) spectra of **Ir-pphen-L⁵-B**, recorded in toluene at room temperature.




Fig. S42. Overlaid, normalized UV–vis absorption (black solid line) and excitation (red dashed line) spectra of **Ir-piq-L**⁷, recorded in toluene at room temperature.




Fig. S43. Overlaid, normalized UV–vis absorption (black solid line) and excitation (red dashed line) spectra of **Ir-piq-L**⁸, recorded in toluene at room temperature.




Figure S44. Photoluminescence decay trace for complex **Ir-btp-L**¹, recorded in toluene solution at room temperature with 390 nm excitation. The raw decay trace is shown in red, with the best-fit line displayed in green.




Figure S45. Photoluminescence decay trace for complex $Ir-btp-L^1$, recorded in PMMA film at room temperature with 390 nm excitation. The raw decay trace is shown in red, with the best-fit line displayed in green.




Figure S46. Photoluminescence decay trace for complex $Ir-btp-L^2$, recorded in toluene solution at room temperature with 390 nm excitation. The raw decay trace is shown in red, with the best-fit line displayed in green.




Figure S47. Photoluminescence decay trace for complex $Ir-btp-L^2$, recorded in PMMA film at room temperature with 390 nm excitation. The raw decay trace is shown in red, with the best-fit line displayed in green.




Figure S48. Photoluminescence decay trace for complex **Ir-pphen-L**¹, recorded in toluene solution at room temperature with 390 nm excitation. The raw decay trace is shown in red, with the best-fit line displayed in green.




Figure S49. Photoluminescence decay trace for complex **Ir-pphen-L**¹, recorded in PMMA film at room temperature with 390 nm excitation. The raw decay trace is shown in red, with the best-fit line displayed in green.




Figure S50. Photoluminescence decay trace for complex Ir-piq-L⁶, recorded in toluene solution at room temperature with 390 nm excitation. The raw decay trace is shown in red, with the best-fit line displayed in green.




Figure S51. Photoluminescence decay trace for complex **Ir-piq-L**⁶, recorded in PMMA film at room temperature with 390 nm excitation. The raw decay trace is shown in red, with the best-fit line displayed in green.




Figure S52. Photoluminescence decay trace for complex **Ir-piq-L³H-B**, recorded in toluene solution at room temperature with 390 nm excitation. The raw decay trace is shown in red, with the best-fit line displayed in green.




Figure S53. Photoluminescence decay trace for complex **Ir-piq-L³H-B**, recorded in PMMA film at room temperature with 390 nm excitation. The raw decay trace is shown in red, with the best-fit line displayed in green.




Figure S54. Photoluminescence decay trace for complex **Ir-piq-L⁴-B**, recorded in toluene solution at room temperature with 390 nm excitation. The raw decay trace is shown in red, with the best-fit line displayed in green.




Figure S55. Photoluminescence decay trace for complex **Ir-piq-L⁴-B**, recorded in PMMA film at room temperature with 390 nm excitation. The raw decay trace is shown in red, with the best-fit line displayed in green.




Figure S56. Photoluminescence decay trace for complex Ir-pphen-L⁵, recorded in toluene solution at room temperature with 390 nm excitation. The raw decay trace is shown in red, with the best-fit line displayed in green.




Figure S57. Photoluminescence decay trace for complex **Ir-pphen-L**⁵, recorded in PMMA film at room temperature with 390 nm excitation. The raw decay trace is shown in red, with the best-fit line displayed in green.




Figure S58. Photoluminescence decay trace for complex Ir-pphen-L⁵-B, recorded in toluene solution at room temperature with 390 nm excitation. The raw decay trace is shown in red, with the best-fit line displayed in green.




Figure S59. Photoluminescence decay trace for complex **Ir-pphen-L⁵-B**, recorded in PMMA film at room temperature with 390 nm excitation. The raw decay trace is shown in red, with the best-fit line displayed in green.




Figure S60. Photoluminescence decay trace for complex **Ir-piq-L**⁷, recorded in toluene solution at room temperature with 390 nm excitation. The raw decay trace is shown in red, with the best-fit line displayed in green.




Figure S61. Photoluminescence decay trace for complex **Ir-piq-L**⁷, recorded in PMMA film at room temperature with 390 nm excitation. The raw decay trace is shown in red, with the best-fit line displayed in green.




Figure S62. Photoluminescence decay trace for complex Ir-piq-L⁸, recorded in toluene solution at room temperature with 390 nm excitation. The raw decay trace is shown in red, with the best-fit line displayed in green.




Figure S63. Photoluminescence decay trace for complex Ir-piq-L⁸, recorded in PMMA film at room temperature with 390 nm excitation. The raw decay trace is shown in red, with the best-fit line displayed in green.

ESI References

- 1 M. Nonoyama, Benzo[h]quinolin-10-yl-N Iridium(III) Complexes, BCSJ, 1974, 47, 767-768.
- 2C. Jiang, S. Yoon, Y. H. Nguyen and T. S. Teets, Modular Imine Chelates with Variable Anionic Donors Promote Red Phosphorescence in Cyclometalated Iridium Complexes, *Inorg. Chem.*, 2023, **62**, 11278–11286.
- 3X. Meng, Y.-J. Lin and G.-X. Jin, Syntheses and molecular structures of 18/16-electron halfsandwich iridium(III) complexes with chelating anilido-imine ligands, *Journal of Organometallic Chemistry*, 2008, **693**, 2597–2602.
- 4B. C. E. Makhubela, A. M. Jardine, G. Westman and G. S. Smith, Hydroformylation of 1octene using low-generation Rh(I) metallodendritic catalysts based on a tris-2-(2pyridyliminoethyl)amine scaffold, *Dalton Trans.*, 2012, **41**, 10715–10723.
- 5 P. Altmann, M. Cokoja and F. E. Kühn, Halide substituted Schiff-bases: Different activities in methyltrioxorhenium(VII) catalyzed epoxidation via different substitution patterns, *Journal of Organometallic Chemistry*, 2012, **701**, 51–55.
- 6P. G. Seybold and M. Gouterman, Porphyrins: XIII: Fluorescence spectra and quantum yields, *Journal of Molecular Spectroscopy*, 1969, **31**, 1–13.
- 7G. M. Sheldrick, Crystal structure refinement with SHELXL, Acta Cryst C, 2015, 71, 3-8.
- 8A. L. Spek, Structure validation in chemical crystallography, Acta Cryst D, 2009, 65, 148–155.